Alkermes plc (ALKS)
ALKSNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$46.55
+0.3900 (+0.84%) today
At the close, Nov 10, 3:59 PM ET. After hours $46.47 –
- Market cap
- $7.81bn
- P/E
- 1551.7
- EPS, last 4 quarters
- $0.0300
- Dividend yield
- –
- Day range
- $45.35 to $46.57
- 52-week range
- $27.00 to $55.67
- Average volume
- 2.02m
- Previous close
- $46.16
Analysts
12 coveringBuy8 buy, 3 hold, 1 sell
Targets a year out average $61.73, +32.6% from here
Earnings
next estimate $-0.1500Next report
Dec 2025
+9.7%
Mar 2026
+29.8%
Jun 2026
+100.0%
Sep 2026
+212.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $384.55m | $392.91m | $496.01m | $480.13m |
| Gross profit | $338.34m | $331.33m | $397.90m | $385.91m |
| Operating income | $58.10m | -$48.28m | $18.35m | $36.02m |
| Net income | $49.34m | -$66.48m | $501.0k | $16.29m |
Last four quarters: revenue $1.75bn, margin -0.0%, free cash flow $227.37m
News
8 latest- Alkermes Records Lower Q3 Profit At $16 Mln Despite Higher Product Revenues RTTNews · 6 days ago
- Alkermes (ALKS) Q3 2026 Earnings Call TranscriptThe Motley Fool · 7 days ago
- What Alkermes (ALKS) Said on Its Q3 Earnings CallMarketBeat · Nov 3, 2026
- Alkermes plc Reports Third Quarter 2026 Financial ResultsFintel · Nov 3, 2026
- Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to SayZacks · Nov 3, 2026
- Alkermes (ALKS) Surpasses Q3 Earnings and Revenue EstimatesZacks · Nov 3, 2026
- Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top EstimatesZacks · Oct 29, 2026
- Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to DeclineZacks · Oct 27, 2026
The company
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes has established a leadership position in orexin biology and is advancing a portfolio of investigational orexin 2 receptor agonists for narcolepsy, idiopathic hypersomnia and other psychiatric and neurological disorders, including attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) and fatigue associated with multiple sclerosis and Parkinson's disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- alkermes.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.